复发/难治性套细胞淋巴瘤的治疗选择
本综述讨论复发套细胞淋巴瘤的管理,重点涵盖共价BTK抑制剂在首次或后续复发中的支持数据,描述BTK抑制剂进展后的结局及耐药机制与后续选择。文中还讨论抗CD19 CAR-T疗法、异基因干细胞移植及非共价BTK抑制剂、ROR1抗体药物偶联物和双特异性抗体等新疗法。
要点
- 共价BTK抑制剂是复发MCL首次或后续复发的重要治疗选择。
- BTK抑制剂耐药机制及进展后治疗选择需个体化,考虑可及性、偏好、年龄和合并症。
- 抗CD19 CAR-T、异基因移植及非共价BTK抑制剂等新疗法正在快速发展。
核心结论
- 复发MCL的治疗需结合共价BTK抑制剂、CAR-T、异基因移植及多种新疗法进行个体化选择。
研究设计与样本
- 综述,讨论复发MCL的关键治疗路径及支持数据。
主要发现
- 共价BTK抑制剂在首次或后续复发中具有支持数据。
- 文中描述了经BTK抑制剂进展患者的结局及共价BTKi耐药机制。
- 抗CD19 CAR-T、异基因干细胞移植、非共价可逆BTK抑制剂、ROR1抗体药物偶联物和双特异性抗体等受到讨论。
临床怎么用
- 复发MCL治疗选择可取决于治疗可及性、患者和医生偏好以及患者年龄和合并症状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which immunochemotherapy, with or without high-dose therapy, and autologous stem cell transplantation remain standard frontline therapies. Despite their clear efficacy, patients inevitably relapse and require subsequent therapy. In this review, we discuss the key therapeutic approaches in the management of relapsed MCL, covering in depth the data supporting the use of covalent Bruton tyrosine kinase (BTK) inhibitors at first or subsequent relapse. We describe the outcomes of patients progressing through BTK inhibitors and discuss the mechanisms of covalent BTKi resistance and treatment options after covalent treatment with BTKi. Options in this setting may depend on treatment availability, patient's and physician's preference, and the patient's age and comorbidity status. We discuss the rapid recent development of anti-CD19 chimeric antigen receptor T-cell therapy, as well as the utility of allogenic stem cell transplantation and novel therapies, such as noncovalent, reversible BTK inhibitors; ROR1 antibody drug conjugates; and bispecific antibodies.
引用
- Eyre TA, Cheah CY, Wang ML, et al. Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood. 2022. PMID: 34679161. doi:10.1182/blood.2021013326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。